Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Saved in:
Bibliographic Details
Title: Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Authors: Ngaimisi, E (AUTHOR), Minzi, O (AUTHOR), Mugusi, S (AUTHOR), Sasi, P (AUTHOR), Riedel, K-D (AUTHOR), Suda, A (AUTHOR), Ueda, N (AUTHOR), Bakari, M (AUTHOR), Janabi, M (AUTHOR), Mugusi, F (AUTHOR), Bertilsson, L (AUTHOR), Burhenne, J (AUTHOR), Aklillu, E (AUTHOR), Diczfalusy, U (AUTHOR)
Source: Journal of Antimicrobial Chemotherapy (JAC). Dec2014, Vol. 69 Issue 12, p3311-3319. 9p.
Database: Environment Complete
Description
ISSN:03057453
DOI:10.1093/jac/dku286